Effects of PERMISSive Lung-protective Ventilation on Outcome in Critically Ill Invasively Ventilated Patients

NCT ID: NCT07077174

Last Updated: 2025-09-03

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: NA
• Total Enrollment: 84 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2025-08-31
• Study Completion Date: 2026-08-31

Brief Summary

RATIONALE Lung-protective ventilation using a lower respiratory rate (RR) is an appealing strategy to reduce ventilation intensity, which may require permissive hypercapnia. However, the feasibility and safety of this so-called 'permissive lung-protective ventilation' must be investigated, before conducting a large randomized clinical trial to evaluate its effectiveness on patient-centered outcomes.

OBJECTIVE To study the feasibility and safety of permissive lung-protective ventilation in adult critically ill patients receiving invasive ventilation for acute hypoxemic respiratory failure, and to inform the design of a future randomized clinical trial in this patient population.

HYPOTHESIS Permissive lung-protective ventilation is a feasible and safe ventilation strategy.

STUDY DESIGN Multicenter, randomized clinical pilot trial. STUDY POPULATION Critically ill patients, aged > 18 years, intubated for acute hypoxemic respiratory failure, and expected to receive ventilation for > 24 hours.

METHODS Patients are randomized to permissive lung-protective ventilation wherein RR is stepwise reduced, or to conventional lung-protective ventilation.

OUTCOME MEASURES The primary endpoint is feasibility, assessed by the difference in respiratory rate (RR) between the two groups, from the start of mechanical ventilation until first extubation. Secondary endpoints include protocol compliance and feasibility of collecting data, and safety, assessed by the occurrence of unacceptable hypercapnia and hypoxemia and the incidence of ventilator-associated complications SAMPLE SIZE To estimate the appropriate sample size for this pilot study, we considered the primary feasibility endpoint of detecting a difference in the respiratory rate (RR). Assuming an expected mean difference in RR of 7.5, based on previous studies [1, 2], with an SD of 10, a power of 90% and an alpha of 0.05, with a drop-out rate estimated at 10%, a two-tailed t-test was used. The required sample size is 84 patients (42 patients per group).

NATURE AND EXTENT OF THE BURDEN AND RISKS ASSOCIATED WITH PARTICIPATION, BENEFIT AND GROUP RELATEDNESS Ventilation with a lower RR may require permissive hypercapnia, which, when kept within safe limits, is safe. In current daily practice, there is no guidance in setting RR; consequently, RR varies widely across patients and is often set high. This pilot study compares two forms of lung-protective ventilation, both considered standard care in current ICU practice. The control group receives conventional ventilation with low tidal volumes and high RR to maintain normal PaCO₂ and pH. The intervention group, permissive ventilation, uses a lower RR to reduce mechanical power, accepting mild hypercapnia and acidosis. Permissive ventilation is most often reserved for patients with severe lung conditions, where ventilator settings are more complex and ventilation intensity is high. In these patients, permissive ventilation is considered safe, and may even be beneficial. We aim to evaluate this strategy more broadly in critically ill patients. The collection of demographic, ventilation and outcome data causes no harm to patients. Blood is drawn for arterial blood gas analysis, but this is also part of standard care.

Conditions

Mechanical Ventilation; Acute Hypoxemic Respiratory Failure; Intensive Care (ICU)

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: SINGLE

Study Groups

Permissive lung-protective ventilation

The goal is to achieve the lowest possible respiratory rate (RR) according to a guideline \< 1 hour after start of ventilation in the ICU.

Group Type: EXPERIMENTAL

Permissive lung-protective ventilation

Intervention Type: OTHER

The goal is to achieve the lowest possible respiratory rate (RR) according to a guideline in which the target RR is estimated by combining the baseline RR with the results of arterial blood gas analysis (ABG), determined by the highest acceptable partial pressure of carbon dioxide (PaCO2) of ≤ 8.5 kPa (64 mmHg) but limited by the lowest acceptable arterial pH (pHa) of \> 7.20. The RR is gradually decreased, in steps of 2 breaths every 10 minutes, based on continuous end-tidal CO2 monitoring. To ensure that the pHa does not fall below 7.20, following randomization, ABGs are repeated every hour until the target RR is reached, for at least 6 hours. Thereafter, blood gas analyses are repeated at least every 8 hours (at the start of every nursing shift). Down-titration of RR stops at a rate of 4 breaths per minute. This approach continues until the switch to spontaneous breathing. Of note, when the pHa is \> 7.50, this must first be decreased to ≤ 7.50 based on local protocol.

Conventional lung-protective ventilation

The respiratory rate is set according to standard of care \< 1 hour after start of ventilation in the ICU.

Group Type: ACTIVE_COMPARATOR

Conventional lung-protective ventilation

Intervention Type: OTHER

Following randomization, which should happen within 1 hour after start of ventilation in the ICU, the RR is set according to standard of care, based on continuous end-tidal CO2 monitoring, to target a normal PaCO2 (4.7-6.4 kPa or 35-48 mmHg) combined with a pHa within the range of 7.35 to 7.45. Following randomization, blood gas analyses are repeated every hour for at least 6 hours, and thereafter at least every 8 hours (at the start of every nursing shift). This approach continues until the weaning phase.

Interventions

Permissive lung-protective ventilation

The goal is to achieve the lowest possible respiratory rate (RR) according to a guideline in which the target RR is estimated by combining the baseline RR with the results of arterial blood gas analysis (ABG), determined by the highest acceptable partial pressure of carbon dioxide (PaCO2) of ≤ 8.5 kPa (64 mmHg) but limited by the lowest acceptable arterial pH (pHa) of \> 7.20. The RR is gradually decreased, in steps of 2 breaths every 10 minutes, based on continuous end-tidal CO2 monitoring. To ensure that the pHa does not fall below 7.20, following randomization, ABGs are repeated every hour until the target RR is reached, for at least 6 hours. Thereafter, blood gas analyses are repeated at least every 8 hours (at the start of every nursing shift). Down-titration of RR stops at a rate of 4 breaths per minute. This approach continues until the switch to spontaneous breathing. Of note, when the pHa is \> 7.50, this must first be decreased to ≤ 7.50 based on local protocol.

Intervention Type: OTHER

Conventional lung-protective ventilation

Following randomization, which should happen within 1 hour after start of ventilation in the ICU, the RR is set according to standard of care, based on continuous end-tidal CO2 monitoring, to target a normal PaCO2 (4.7-6.4 kPa or 35-48 mmHg) combined with a pHa within the range of 7.35 to 7.45. Following randomization, blood gas analyses are repeated every hour for at least 6 hours, and thereafter at least every 8 hours (at the start of every nursing shift). This approach continues until the weaning phase.

Intervention Type: OTHER

Eligibility Criteria

Inclusion Criteria

• admission to one of the participating ICUs;
• intubated and receiving invasive ventilation for acute hypoxemic respiratory failure;
• expected duration of ventilation of at least 24 hours and
• receiving invasive ventilation ≤ 1 hour.

Exclusion Criteria

• age below 18 years;
• intubated and receiving invasive ventilation for other reasons than acute hypoxemic respiratory failure;
• receiving or planned to receive veno-venous, veno-arterial or arterio-venous extracorporeal membrane oxygenation (ECMO);
• having COPD GOLD III and IV;
• contra-indication for hypercapnia, such as ongoing cardiac ischemia (as defined in the guideline of the European Society of Cardiology), or having suspected or confirmed increased intracranial pressure due to brain injury, judged by the attending physician;
• having metabolic acidosis, with a pH < 7.20 and judged by the attending physician to have a metabolic cause;
• after cardiac resuscitation;
• any neurologic diagnosis that can prolong duration of mechanical ventilation, e.g., Guillain-Barré syndrome, high spinal cord lesion or amyotrophic lateral sclerosis, multiple sclerosis, or myasthenia gravis;
• suspected or confirmed pregnancy;
• participation in another interventional trial using similar endpoints;
• previously randomized in this study;
• no informed consent; or
• admitted for terminal care

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Reinier de Graaf Groep

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Laura Buiteman-Kruizinga, RN, PhD

Role: PRINCIPAL_INVESTIGATOR

Reinier de Graaf Groep

Marcus J. Schultz, MD, PhD

Role: STUDY_CHAIR

Amsterdam UMC

Locations

ZiekenhuisGroep Twente

Almelo, , Netherlands

Site Status: NOT_YET_RECRUITING

Reinier de Graaf Hospital

Delft, , Netherlands

Site Status: RECRUITING

Dijklander Hospital

Hoorn, , Netherlands

Site Status: NOT_YET_RECRUITING

Vall d'Hebron

Barcelona, , Spain

Site Status: NOT_YET_RECRUITING

Countries

Netherlands; Spain

Central Contacts

Laura A. Buiteman-Kruizinga, RN, PhD

Role: CONTACT

l.kruizinga@rdgg.nl

+31152604040

Facility Contacts

Ellen Platenkamp, RN

Role: primary

researchic@zgt.nl

+3188 708 35 92

Laura A. Buiteman-Kruizinga, RN, PhD

Role: primary

l.kruizinga@rdgg.nl

+152604040

Stephanie S. List, RN

Role: primary

s.s.list@dijklander.nl

+31229 - 257 799

Luis Morales, MD, PhD

Role: primary

luchomq2077@gmail.com

+34 934 89 30 00

Other Identifiers

NL-OMON57603

Identifier Type: OTHER

Identifier Source: secondary_id

NL-009624.P25.028

Identifier Type: -

Identifier Source: org_study_id